These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33011209)

  • 21. The impact of RASopathy-associated mutations on CNS development in mice and humans.
    Kang M; Lee YS
    Mol Brain; 2019 Nov; 12(1):96. PubMed ID: 31752929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic defects of the growth-hormone-IGF axis associated with growth hormone insensitivity.
    Woods K
    Endocr Dev; 2007; 11():6-15. PubMed ID: 17986822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic landscape of RASopathies in Chinese: Three decades' experience in Hong Kong.
    Yu KPT; Luk HM; Leung GKC; Mak CCY; Cheng SSW; Hau EWL; Chan DKH; Lam STS; Tong TMF; Chung BHY; Lo IFM
    Am J Med Genet C Semin Med Genet; 2019 Jun; 181(2):208-217. PubMed ID: 30896080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Malignancy in Noonan syndrome and related disorders.
    Smpokou P; Zand DJ; Rosenbaum KN; Summar ML
    Clin Genet; 2015 Dec; 88(6):516-22. PubMed ID: 25683281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/MAPK pathway.
    Jorge AA; Malaquias AC; Arnhold IJ; Mendonca BB
    Horm Res; 2009; 71(4):185-93. PubMed ID: 19258709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics.
    Rauen KA; Alsaegh A; Ben-Shachar S; Berman Y; Blakeley J; Cordeiro I; Elgersma Y; Evans DG; Fisher MJ; Frayling IM; George J; Huson SM; Kerr B; Khire U; Korf B; Legius E; Messiaen L; van Minkelen R; Nampoothiri S; Ngeow J; Parada LF; Phadke S; Pillai A; Plotkin SR; Puri R; Raji A; Ramesh V; Ratner N; Shankar SP; Sharda S; Tambe A; Vikkula M; Widemann BC; Wolkenstein P; Upadhyaya M
    Am J Med Genet A; 2019 Jun; 179(6):1091-1097. PubMed ID: 30908877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Rasopathies: developmental disorders that predispose to cancer and skin manifestations].
    Hernández-Martín A; Torrelo A
    Actas Dermosifiliogr; 2011; 102(6):402-16. PubMed ID: 21536246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone.
    Winston LA; Hunter T
    J Biol Chem; 1995 Dec; 270(52):30837-40. PubMed ID: 8537333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin-like growth factor binding protein-3 generation: an index of growth hormone insensitivity.
    Thalange NK; Price DA; Gill MS; Whatmore AJ; Addison GM; Clayton PE
    Pediatr Res; 1996 May; 39(5):849-55. PubMed ID: 8726240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic disorders of GH action pathway.
    Domené HM; Fierro-Carrión G
    Growth Horm IGF Res; 2018 Feb; 38():19-23. PubMed ID: 29249625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to growth hormone in short children with Noonan syndrome: correlation to genotype.
    Binder G
    Horm Res; 2009 Dec; 72 Suppl 2():52-6. PubMed ID: 20029239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
    Aoki Y; Niihori T; Narumi Y; Kure S; Matsubara Y
    Hum Mutat; 2008 Aug; 29(8):992-1006. PubMed ID: 18470943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth, Endocrine Features, and Growth Hormone Treatment in Noonan Syndrome.
    Dahlgren J; Noordam C
    J Clin Med; 2022 Apr; 11(7):. PubMed ID: 35407641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
    Tidyman WE; Rauen KA
    Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Noonan syndrome: genetic and clinical update and treatment options].
    Carcavilla A; Suárez-Ortega L; Rodríguez Sánchez A; Gonzalez-Casado I; Ramón-Krauel M; Labarta JI; Quinteiro Gonzalez S; Riaño Galán I; Ezquieta Zubicaray B; López-Siguero JP
    An Pediatr (Engl Ed); 2020 Jul; 93(1):61.e1-61.e14. PubMed ID: 32493603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MECHANISMS IN ENDOCRINOLOGY: Novel genetic causes of short stature.
    Wit JM; Oostdijk W; Losekoot M; van Duyvenvoorde HA; Ruivenkamp CA; Kant SG
    Eur J Endocrinol; 2016 Apr; 174(4):R145-73. PubMed ID: 26578640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Manifestations of Noonan Syndrome and Related Disorders.
    Breilyn MS; Mehta L
    Pediatr Endocrinol Rev; 2019 May; 16(Suppl 2):428-434. PubMed ID: 31115194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Copy number variants including RAS pathway genes-How much RASopathy is in the phenotype?
    Lissewski C; Kant SG; Stark Z; Schanze I; Zenker M
    Am J Med Genet A; 2015 Nov; 167A(11):2685-90. PubMed ID: 25974318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-1 inhibits the induction of insulin-like growth factor-I by growth hormone in CWSV-1 hepatocytes.
    Shumate ML; Yumet G; Ahmed TA; Cooney RN
    Am J Physiol Gastrointest Liver Physiol; 2005 Aug; 289(2):G227-39. PubMed ID: 15831712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral blood cells from children with RASopathies show enhanced spontaneous colonies growth in vitro and hyperactive RAS signaling.
    Gaipa G; Bugarin C; Cianci P; Sarno J; Bonaccorso P; Biondi A; Selicorni A
    Blood Cancer J; 2015 Jul; 5(7):e324. PubMed ID: 26186557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.